Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Levosimendan injection

Levosimendan is a cardiac therapeutic drug and is limited to short-term treatment of acute decompensated heart failure with poor standard treatment effect.

This product is only for use in hospitalized patients, and should be used with appropriate medical monitoring equipment and with the ability to use inotropes… Details
A comprehensive interpretation of Zuo Ximendan

This product is indicated for the short-term treatment of acute decompensated heart failure (ADHF) that requires increased myocardial contractility.

This product is intended for use only in hospitalized patients with appropriate medical monitoring equipment and experience with inotropes. This product needs to be diluted before administration. This product is for intravenous infusion only and can be administered via peripheral or central intravenous infusion. The dose and duration of treatment should be adjusted based on the patient’s general condition and clinical manifestations. The initial loading dose of treatment is 6 to 12 μg/kg, and the time should be greater than 10 minutes, followed by a continuous infusion of 0.1 μg/kg/min. For patients taking concomitant vasodilators and/or inotropes, the recommended loading dose at the beginning of treatment is 6 μg/kg. Higher loading doses produce stronger hemodynamic effects and may result in a transient increase in the incidence of adverse reactions. During loading dose administration and within 30 to 60 minutes of continuous administration, closely observe the patient’s reaction. If the reaction is excessive (hypotension, tachycardia), the infusion rate should be reduced to 0.05 μg/kg/min or the administration should be stopped. medicine. If the initial dose is well tolerated and an enhanced hemodynamic effect is required, the infusion rate can be increased to 0.2 μg/kg/min. For patients with severe chronic heart failure in the acute decompensation phase, dosing is usually continued for 24 hours. After discontinuation of levosimendan, no drug resistance or rebound was found. The hemodynamic effects last for at least 24 hours and may last up to 9 days after discontinuation of the drug. The same medicines produced by different manufacturers may have inconsistent instructions. If you find any inconsistency in the drug instructions before taking the medicine, please consult your doctor or pharmacist in time.

Drug contraindications:
Contraindicated during pregnancy, lactation, children, liver and kidney insufficiency, allergy to this product.
Related dosage forms: